Skip to main content
OpenTrials
Completed

NCT Number: NCT00372229

A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation

This 2 arm study will compare the efficacy of 100 days of Valcyte (900mg po daily) prophylaxis with that of no prophylaxis, under the condition of pre-emptive therapy of active CMV infection, in CMV positive renal transplant recipients. The influence of the two prevention concepts on the occurrence of direct and indirect effects of active CMV infections will be compared. The anticipated time on study treatment is 3 months-1 year, and the target sample size is 100-500 individuals.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cytomegalovirus Infections DNA Virus Infections Herpesviridae Infections Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Innsbruck, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • primary or secondary renal allograft within preceding 14 days;
  • IgG seropositive for CMV;
  • receiving immunosuppressive therapy.

Exclusion criteria

  • active CMV infection;
  • current/history of malignancy;
  • acute steroid resistant rejection episode since transplantation.

Treatment and study plan

Valganciclovir CMV Prophylaxis

Drug

900 mg valganciclovir, taken orally once daily, adjusted to renal function starting within 14 days of transplantation until Day 100 after transplantation.

Other names: Valcyte

Valganciclovir (Pre-emptive CMV Therapy)

Drug

If plasma polymerase chain reaction (PCR) ≥ 400 CMV copies/millilitre, then 1800 mg valganciclovir per day adjusted to renal function for at least 14 days until the second negative PCR (below 400 copies/ml) followed by secondary prophylaxis for 28 days with 900 mg valganciclovir adjusted to renal function. If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.

Other names: Valcyte

Ganciclovir

Drug

If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.

Primary outcomes

  1. Percentage of Participants With Active Cytomegalovirus (CMV) Infection Within 12 Months

    Time frame: Up to 12 months

    Active CMV infection was defined as plasma polymerase chain reaction (PCR) ≥ 400 copies/millilitre (ml).

  2. Percentage of Participants With CMV Disease Within 12 Months Including CMV Syndrome and Tissue Invasive Disease

    Time frame: Up to 12 months

    CMV disease comprises the two components of CMV syndrome as well as CMV tissue invasive disease. CMV syndrome was defined as viremia according to plasma PCR ≥ 400 copies/ml and at least one of the following signs: fever of ≥38 °C; new or increased malaise (malaise defined as normal activity reduced >50%; cannot work or unable to care for self; leukopenia on 2 successive measurements separated by at least 24 hours thrombocytopenia; elevation of hepatic transaminases (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) to at least 2 x upper limit of normal (ULN). CMV tissue invasive disease was defined as viremia according plasma PCR ≥ 400 copies/ml and clinical evidence of localized CMV infection (CMV inclusion cells or in situ detection of CMV antigen or deoxyribonucleic acid [DNA] by immunostaining or hybridization, respectively), cerebral spinal fluid [CSF]) and/or relevant symptoms or signs of organ dysfunction.

  3. Urine Proteomic Pattern at Month 12

    Time frame: Up to 12 months

    Proteomics is the complete set of proteins expressed by an organism, tissue, or cell. Urine proteomic pattern was measured on a scale between -1, indicating no graft alteration, and +1, indicating graft alteration.

  4. Percentage of Participants With Graft Loss at Month 84

    Time frame: Up to 84 months

Secondary outcomes

  1. Percentage of Participants With CMV Syndrome Within 12 Months

    Time frame: Up to 12 months

    CMV syndrome was defined as viremia according to plasma PCR ≥ 400 copies/ml and at least one of the following signs: fever of ≥38 °C; new or increased malaise (malaise defined as normal activity reduced >50%; cannot work or unable to care for self; leukopenia on 2 successive measurements separated by at least 24 hours thrombocytopenia; elevation of hepatic transaminases (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) to at least 2 x upper limit of normal (ULN).

  2. Percentage of Participants With CMV Tissue Invasive Disease Within 12 Months

    Time frame: Up to 12 months

    CMV tissue invasive disease was defined as viremia: PCR ≥ 400 copies/ml and clinical evidence of localized CMV infection (CMV inclusion cells or in situ detection of CMV antigen or deoxyribonucleic acid [DNA] by immunostaining or hybridization, respectively), cerebral spinal fluid [CSF]) and/or relevant symptoms or signs of organ dysfunction.

  3. Time to Occurrence of First Viremia Within 12 Months

    Time frame: Up to 12 months

    Viremia was defined as plasma PCR ≥ 400 copies/ml.

  4. Viral Burden at Viremia

    Time frame: Up to 12 months

    Time-weighted area under the curve (AUC) of the polymerase chain reaction (PCR). Viremia was defined as plasma PCR ≥ 400 copies/ml.

  5. Creatinine Clearance at Month 12

    Time frame: Up to 12 months

    Creatinine clearance was estimated using the Cockcroft-Gault formula.

  6. Percentage of Participants With at Least One Treated and Biopsy-Proven Acute Rejection Episode Within 12 Months

    Time frame: Up to 12 months

  7. Days of Hospitalization

    Time frame: Up to 12 months

  8. Relationship Between Proteomics Pattern and Graft Survival

    Time frame: Up to 12 months

    Proteomics is the complete set of proteins expressed by an organism, tissue, or cell. The proteomics of CKD273, CMV, and nephropathy was measured on a scale between -1, indicating no graft alteration, and +1, indicating graft alteration.

  9. Relationship Between Proteomics Pattern and Participant Survival

    Time frame: Up to 12 months

    Proteomics is the complete set of proteins expressed by an organism, tissue, or cell. The proteomics of CKD273, CMV, and nephropathy was measured on a scale between -1, indicating no graft alteration, and +1, indicating graft alteration.

  10. Proteomics Parameter: CKD273

    Time frame: Up to 12 months

    Proteomics is the complete set of proteins expressed by an organism, tissue, or cell. The proteomics of CKD273 was measured on a scale between -1, indicating no graft alteration, and +1, indicating graft alteration.

  11. Proteomics Parameter: CMV

    Time frame: Up to 12 months

    Proteomics is the complete set of proteins expressed by an organism, tissue, or cell. The proteomics of CMV was measured on a scale between -1, indicating no graft alteration, and +1, indicating graft alteration.

  12. Proteomics Parameter: Nephropathy

    Time frame: Up to 12 months

    Proteomics is the complete set of proteins expressed by an organism, tissue, or cell. The proteomics of nephropathy was measured on a scale between -1, indicating no graft alteration, and +1, indicating graft alteration.

  13. Percentage of Participants Surviving at Month 12

    Time frame: Up to 12 months

  14. Percentage of Participants With Graft Survival at Month 12

    Time frame: Up to 12 months

  15. Percentage of Participants With Leukopenia Within 12 Months

    Time frame: Up to 12 months

    Leukopenia: white blood cell (WBC) of < 3,500/microlitre (μL) and < 1,000/μL

  16. Percentage of Participants With Neutropenia Within 12 Months

    Time frame: Up to 12 months

    Neutropenia: absolute neutrophil count (ANC) < 750/μL within 12 months.

  17. Percentage of Participants With Any Opportunistic Infection Within 12 Months

    Time frame: Up to 12 months

  18. Percentage of Participants With Post-Transplant Diabetes Mellitus

    Time frame: Up to 12 months

  19. Percentage of Participants With Active CMV Infections Not Responding to Valganciclovir or IV Ganciclovir Treatment

    Time frame: Up to 12 months

    Active CMV infection was defined as plasma polymerase chain reaction (PCR) ≥ 400 copies/millilitre (ml).

  20. Number of Participants With CMV Viremia (Active CMV Infection) From Baseline to Month 24 and Every 12 Months up to Month 84

    Time frame: From Month 24 to Month 84

    Viremia (active CMV Infection) was defined as PCR ≥ 400 copies/ml.

  21. Number of Participants With CMV Disease From Baseline to Month 24 and Every 12 Months up to Month 84

    Time frame: From Month 24 to Month 84

    CMV disease comprises the two components of CMV syndrome as well as CMV tissue invasive disease. CMV syndrome was defined as viremia according to plasma PCR ≥ 400 copies/ml and at least one of the following signs: fever of ≥38 °C; new or increased malaise (malaise defined as normal activity reduced >50%; cannot work or unable to care for self; leukopenia on 2 successive measurements separated by at least 24 hours thrombocytopenia; elevation of hepatic transaminases (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) to at least 2 x upper limit of normal (ULN). CMV tissue invasive disease was defined as viremia according plasma PCR ≥ 400 copies/ml and clinical evidence of localized CMV infection (CMV inclusion cells or in situ detection of CMV antigen or deoxyribonucleic acid [DNA] by immunostaining or hybridization, respectively), cerebral spinal fluid [CSF]) and/or relevant symptoms or signs of organ dysfunction.

  22. Number of Participants With CMV Syndrome From Baseline to Month 24 and Every 12 Months up to Month 84

    Time frame: From Month 24 to Month 84

    CMV syndrome was defined as viremia according to plasma PCR ≥ 400 copies/ml and at least one of the following signs: fever of ≥38 °C; new or increased malaise (malaise defined as normal activity reduced >50%; cannot work or unable to care for self; leukopenia on 2 successive measurements separated by at least 24 hours thrombocytopenia; elevation of hepatic transaminases (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) to at least 2 x upper limit of normal (ULN).

  23. Number of Participants With CMV Tissue Invasive Disease From Baseline to Month 24 and Every 12 Months up to Month 84

    Time frame: From Month 24 to Month 84

    CMV tissue invasive disease was defined as viremia according plasma PCR ≥ 400 copies/ml and clinical evidence of localized CMV infection (CMV inclusion cells or in situ detection of CMV antigen or deoxyribonucleic acid [DNA] by immunostaining or hybridization, respectively), cerebral spinal fluid [CSF]) and/or relevant symptoms or signs of organ dysfunction.

  24. Number of Participants With Active CMV Infection After Month 24 and Every 12 Months up to Month 84

    Time frame: From Month 24 to Month 84

    Active CMV infection was defined as plasma polymerase chain reaction (PCR) ≥ 400 copies/millilitre (ml).

  25. Number of Participants With CMV Disease After Month 24 and Every 12 Months up to Month 84

    Time frame: From Month 24 to Month 84

    CMV disease comprises the two components of CMV syndrome as well as CMV tissue invasive disease. CMV syndrome was defined as viremia according to plasma PCR ≥ 400 copies/ml and at least one of the following signs: fever of ≥38 °C; new or increased malaise (malaise defined as normal activity reduced >50%; cannot work or unable to care for self; leukopenia on 2 successive measurements separated by at least 24 hours thrombocytopenia; elevation of hepatic transaminases (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) to at least 2 x upper limit of normal (ULN). CMV tissue invasive disease was defined as viremia according plasma PCR ≥ 400 copies/ml and clinical evidence of localized CMV infection (CMV inclusion cells or in situ detection of CMV antigen or deoxyribonucleic acid [DNA] by immunostaining or hybridization, respectively), cerebral spinal fluid [CSF]) and/or relevant symptoms or signs of organ dysfunction.

  26. Percentage of Participants Surviving at Month 24 and Every 12 Months up to Month 84

    Time frame: From Month 24 to Month 84

  27. Number of Participants Who Died From Months 24 to Month 84

    Time frame: From Month 24 to Month 84

  28. Percentage of Participants With Graft Survival at Month 24 and Every 12 Months up to Month 84

    Time frame: From Month 24 to Month 84

  29. Number of Participants Who Had Lost Their Transplant up to Month 84

    Time frame: From Month 24 to Month 84

  30. Number of Participants With Active CMV Infection Who Had Lost Their Transplant up to Month 84

    Time frame: From Month 24 to Month 84

  31. Number of Participants Without Active CMV Infection Who Had Lost Their Transplant up to Month 84

    Time frame: From Month 24 to Month 84

  32. Kaplan-Meier Estimate of the Percentage of Participants (With Versus Without Active CMV Infection) on Valganciclovir CMV Prophylaxis With First Occurrence of Graft Loss at Month 84

    Time frame: Up to 84 months

    An analysis for the time to first occurrence of graft loss within month 84 (by means of Kaplan-Meier analysis) was done for all patients who suffered at least once from acute CMV infection (CMV viremia) during this study versus all patients who did not suffer from acute CMV infection (CMV viremia) during the study. Active CMV infection was defined as plasma polymerase chain reaction (PCR) ≥ 400 copies/millilitre (ml).

  33. Kaplan-Meier Estimate of the Percentage of Participants (With Versus Without Active CMV Infection) on Pre-emptive CMV Therapy With First Occurrence of Graft Loss at Month 84

    Time frame: Up to 84 months

    An analysis for the time to first occurrence of graft loss within month 84 (by means of Kaplan-Meier analysis) was done for all patients who suffered at least once from acute CMV infection (CMV viremia) during this study versus all patients who did not suffer from acute CMV infection (CMV viremia) during the study. Active CMV infection was defined as plasma polymerase chain reaction (PCR) ≥ 400 copies/millilitre (ml).

  34. Number of Participants Who Had Lost Their Transplant or Died up to Month 84

    Time frame: From Month 24 to Month 84

  35. Percentage of Participants With Graft Survival or Participant Survival at Month 24 and Every 12 Months up to Month 84

    Time frame: From Month 24 to Month 84

  36. Number of Participants With Graft Rejections by CMV Status (Positive or Negative) of the Donor at Month 24 and Every 12 Months up to Month 84

    Time frame: From Month 24 to Month 84

  37. Number of Graft Rejections by CMV Status (Positive or Negative) of the Donor at Month 24 and Every 12 Months up to Month 84

    Time frame: From Month 24 to Month 84

  38. Creatinine Clearance at Month 24 and Every 12 Months up to Month 84

    Time frame: From Month 24 to Month 84

    Creatinine Clearance estimated by Cockcroft-Gault formula.

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration

Important dates

Study start
2006
Primary completion
2015
Study completion
2015
First posted
Sep 6, 2006
Registry last updated
Mar 11, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.